NCT06617923View on ClinicalTrials.gov

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 6, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

December 31, 2029

Conditions
Ovary CancerFallopian Tube CancerPrimary Peritoneal Cavity Cancer
Interventions
DRUG

Senaparib

Participants will receive orally 80mg daily Days 1-28 of a 28 day cycle.

DRUG

Temozolomide

Participants will receive orally 20mg daily Days 1-21 of a 28 day cycle.

Trial Locations (1)

21231-2410

RECRUITING

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

Impact Therapeutics
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Impact Therapeutics

UNKNOWN

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT06617923 - Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer | Biotech Hunter | Biotech Hunter